<a href="https://www.fiercebiotech.com/biotech/secretive-cancer-biotech-treeline-steps-out-shadows-reverse-merger" hreflang="en">Clinical-stage cancer biotech Treeline sees path to public markets via reverse merger</a>
Treeline Biosciences plans to go public through a reverse merger with Standard BioTools, aiming for a Nasdaq listing under the ticker TRLN. The merger, expected to close later this year, will provide Treeline with $900 million in cash to support its clinical programs in oncology and other areas.
Treeline Biosciences, a clinical-stage cancer biotech, is set to go public via a reverse merger with Standard BioTools, aiming for a Nasdaq listing under the ticker TRLN. This strategic move is poised to secure Treeline with $900 million in cash, enabling it to sustain operations until 2029, and positions the company for significant growth and development in the coming years, especially with promising assets like the pan-KRAS inhibitor TLN-372. This represents a notable opportunity for investment in a catalyst-rich biotech with substantial potential in oncology, neurology, and immunology.